埃兰科公司的ZenreliaTM,一种用于治疗犬类过敏性皮肤炎的JAK抑制剂,获得FDA批准. Elanco's Zenrelia™, a JAK inhibitor for canine allergic dermatitis, receives FDA approval.

埃兰科动物健康已获得FDA批准ZenreliaTM (伊隆西替尼),该药用于每天服用一次,治疗12个月以上的狗的过敏性和亚托皮性皮炎. Elanco Animal Health has received FDA approval for Zenrelia™ (ilunocitinib), a once-daily oral treatment for allergic and atopic dermatitis in dogs over 12 months old. 这个JAK抑制剂有效地管理了痒痒和炎症,从第一剂剂量中可以明显看出结果。 This JAK inhibitor effectively manages itching and inflammation, with visible results from the first dose. Zenrelia比目前的治疗更负担得起,并尽量减少反弹痒风险。 Zenrelia is more affordable than current treatments and minimizes rebound itch risks. 其启动旨在满足对改善犬类健康皮肤学选择的需求,使数百万受影响狗受益。 Its launch aims to meet the demand for better dermatological options in canine health, benefiting millions of affected dogs.